Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07613840 · ClinicalTrials.gov registry record · NA
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
A NA study, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 484
- Enrollment target
NCT07613840: Recruiting NA study, sponsored by Massachusetts General Hospital.
NCT07613840 is a NA study that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 484 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07613840, a NA study, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 484 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore blood flow to their legs. The main questions it aims to answer are: * Does the personalized plan lower the rate of blood clots in the treated leg one year after the procedure? * Does the personalized plan lower rates of amputation, repeat procedures, bleeding, and death compared to standard treatment? Researchers will compare the personalized TARGET plan which uses a blood test to tailor each person's blood clot prevention medication to the standard treatment to see if the personalized approach works better. Participants will: * Be randomly assigned to either the personalized TARGET plan or standard treatment after their procedure * Have blood tests at 1 week and at 1, 3, 6, 9, and 12 months after their procedure * Have medications adjusted based on blood test results if assigned to the TARGET group
Interventions
- DRUG Aspirin
- DRUG Clopidogrel
- DRUG Rivaroxaban
- DRUG Ticagrelor
- DEVICE Thromboelastography with Platelet Mapping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07613840
The ClinicalTrials.gov registry entry for NCT07613840 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aspirin is the first listed.
NCT07613840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07613840 about?
NCT07613840 is a clinical study titled "Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease". The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore blood flow to their legs. The main questions it aims to answer are: *...
What is the current status of trial NCT07613840?
This trial is currently recruiting. It is a NA study. The enrollment target is 484 participants. The study started on 2025-04-29. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT07613840?
The interventions under investigation include: Aspirin (DRUG), Clopidogrel (DRUG), Rivaroxaban (DRUG), Ticagrelor (DRUG), Thromboelastography with Platelet Mapping (DEVICE).
Who is sponsoring clinical trial NCT07613840?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.